Linked Life Data

12735134

Source:http://linkedlifedata.com/resource/pubmed/id/12735134

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
1
pubmed:dateCreated
2003-5-8
pubmed:abstractText
Single-agent Adriamycin gives a response rate of around 15% to 20%, and with combination therapy, this figure rises to around 20% to 35%; however, there is no proven survival benefit. Nonetheless, HCC is clearly not entirely chemotherapy resistant and complete pathologic remission is possible after systemic combination chemotherapy alone. Major methodologic problems remain in assessment of response and the survival benefit from systemic therapy. Until these are resolved, the answer to the question posed in this article is unknown; further appropriate studies remain to be undertaken.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jan
pubmed:issn
1055-3207
pubmed:author
pubmed:issnType
Print
pubmed:volume
12
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
127-34
pubmed:dateRevised
2006-4-24
pubmed:meshHeading
pubmed:year
2003
pubmed:articleTitle
Are there indications for chemotherapy in hepatocellular carcinoma?
pubmed:affiliation
Division of Cancer Studies, School of Medicine, University of Birmingham, United Kingdom. johnsonp@cancer.Dham.ac.uk
pubmed:publicationType
Journal Article, Review